Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1984 2
1986 1
1989 1
1990 3
1991 1
1992 3
1993 3
1997 2
1998 2
1999 1
2000 2
2001 3
2002 2
2003 1
2004 4
2005 7
2006 10
2007 4
2008 2
2009 1
2010 3
2011 3
2012 5
2013 4
2014 11
2015 16
2016 7
2017 8
2018 10
2019 5
2020 5
2021 6
2022 8
2023 13

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Results by year

Filters applied: . Clear all
Page 1
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, Coskun T, Thomas MK, Mather KJ, Haupt A, Milicevic Z. Heise T, et al. Among authors: thomas mk. Lancet Diabetes Endocrinol. 2022 Jun;10(6):418-429. doi: 10.1016/S2213-8587(22)00085-7. Epub 2022 Apr 22. Lancet Diabetes Endocrinol. 2022. PMID: 35468322 Clinical Trial.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. Coskun T, et al. Among authors: thomas mk. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9. doi: 10.1016/j.cmet.2022.07.013. Epub 2022 Aug 18. Cell Metab. 2022. PMID: 35985340 Free article.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. Urva S, et al. Among authors: thomas mk. Lancet. 2022 Nov 26;400(10366):1869-1881. doi: 10.1016/S0140-6736(22)02033-5. Epub 2022 Oct 27. Lancet. 2022. PMID: 36354040 Clinical Trial.
The need for unrealistic experiments in global change biology.
Collins S, Whittaker H, Thomas MK. Collins S, et al. Among authors: thomas mk. Curr Opin Microbiol. 2022 Aug;68:102151. doi: 10.1016/j.mib.2022.102151. Epub 2022 May 4. Curr Opin Microbiol. 2022. PMID: 35525129 Free article. Review.
Toward an integration of evolutionary biology and ecosystem science.
Matthews B, Narwani A, Hausch S, Nonaka E, Peter H, Yamamichi M, Sullam KE, Bird KC, Thomas MK, Hanley TC, Turner CB. Matthews B, et al. Among authors: thomas mk. Ecol Lett. 2011 Jul;14(7):690-701. doi: 10.1111/j.1461-0248.2011.01627.x. Epub 2011 May 9. Ecol Lett. 2011. PMID: 21554512 Review.
Developmental aspects of the endocrine pancreas.
Kemp DM, Thomas MK, Habener JF. Kemp DM, et al. Among authors: thomas mk. Rev Endocr Metab Disord. 2003 Mar;4(1):5-17. doi: 10.1023/a:1021809917576. Rev Endocr Metab Disord. 2003. PMID: 12618555 Review. No abstract available.
145 results